Human Papillomavirus Testing Market – Overview
The global human papillomavirus testing market is projected to rise at a healthy rate from 2021 to 2031 (forecast period). The increased global prevalence of cervical cancer is a major factor projected to drive the global human papillomavirus testing market during the forecast period. As per the World Health Organization, cervical cancer is the fourth most frequent cancer in women, accounting for 6.6% of all female cancers. Roughly 90% of cervical cancer deaths occur in the middle- to low-income nations.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B...
Furthermore, as per the American Cancer Society, 13,170 new instances of invasive cervical cancer were diagnosed, and 4,250 deaths occurred from cervical cancer in the United States in 2019. As a result, the rising number of cervical cancer cases worldwide is projected to propel the global human papillomavirus testing market.
Human Papillomavirus Testing Market – Competitive Landscape
Key players in the global human papillomavirus testing market are Biomedical Diagnostics, Abbott, bioMerieux, CeMines, Gen-Probe, Bio-Rad, Epigenomics, CanAG Diagnostics, Fujirebio, Guided Therapeutics, Ipsogen, J&J Diagnostics, OncoLab, Hologic, Qiagen, Radient, Pharmaceuticals, Polartechnics, Targeted Diagnostics & Therapeutics, Roche, Sequenom, and Siemens Healthcare.
Key players are adopting different strategies, including creative awareness efforts combined with treatment methods such as vaccination and monoclonal antibodies. Moreover, key players are adopting and adhering to updated cervical screening guidelines to maintain and improve their market position.
Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=c...
Human Papillomavirus Testing Market – Trends and Opportunities
The worldwide human papillomavirus testing market is likely to rise at a rapid pace due to the growing frequency of cervical cancer. Moreover, the rise in the global geriatric female population is also expected to drive the human papillomavirus testing market, owing to the prevalence of co-morbidities in senior females. Human papillomavirus is one of the primary causes of cancer worldwide. Hence, there is an increasing demand for diagnostic innovation to detect human papillomavirus (HPV)-associated malignancy. As a result, increased knowledge about the connection between the human papillomavirus and cervical cancer and an unmet need for precision in diagnostic testing are expected to propel the human papillomavirus testing market.
Moreover, the inability of primary screening tests to detect human papillomavirus due to low sensitivity and false-negative results is projected to positively impact the global human papillomavirus testing market. The existing human papillomavirus vaccine cannot protect the female population from cervical cancer, which is expected to boost market development even among human papillomavirus vaccinated women.
Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=E...
Furthermore, due to a lack of ability and resources, developing nations have significant hurdles in implementing cytology-based screening programs. Cytology-based screening programs necessitate a well-established infrastructure for sample processing and interpretation. Cytology-based screening programs require robust healthcare infrastructure, thorough training, and quality control for efficient outcomes. Conventional cytology screening tests have a medium sensitivity of 44% to 78%; however, HPV DNA testing has a high sensitivity of 66% to 100%. Due to the great sensitivity of the HPV test, screening intervals can be increased, allowing for greater screening coverage in high-risk populations. Moreover, new approaches, such as HPV testing have evolved due to the failure of cytology-based screening programs in low-resource settings.
Human Papillomavirus Testing Market – Regional Landscape
The North America human papillomavirus testing market is projected to grow due to the rising prevalence of cancer and the government's early diagnosis and treatment awareness efforts. Moreover, in the United States, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides free or low-cost breast and cervical cancer screening to women without health insurance. This initiative aims to increase the number of women undergoing screening for cancer.
The Asia Pacific human papillomavirus testing market is likely to experience significant growth due to the rising frequency of cervical cancer and other sexually transmitted illnesses such as chancroid, HSV, and HIV. Moreover, the rise in fatality rates due to human papillomavirus transmission and infection is also one of the factors expected to drive significant growth in the human papillomavirus testing market over the forecast period.
About Us Section:
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!
Contact Us
Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/